I actually think this is a big event but not for share price. We have oncologists and researchers from all over the world attending ASCO. As the trial progresses past phase 1 and enters combined drug and possibly a stand alone trial. We will need patients for these trials to progress quicker especially for more rare diagnosis such as retinoblastoma.

An oncologist six months from now could get a patient that meets the criteria for a trial and remember they saw a trial at ASCO and send over a referral.

And of course these researchers and oncologists could be investors also.